SEC Form 4 · accession 0001209191-17-047756
Insys Therapeutics, Inc. · INSY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Patrick Fourteau
Director
Period of report
Aug 4, 2017
Accepted (ET)
Aug 4, 2017 · 5:33 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001516479
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 4, 2017 | M | 10,000 | $1.62 | A | 69,682 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1,F2 | $1.62 | Aug 4, 2017 | M | 10,000 | D | — | Mar 27, 2021 | Common Stock | 10,000 | 63,770 | D |
Explanation of responses
- F1The exercise price reflects a 3-for-2 forward stock split effected by the Issuer on March 28, 2014 and a 2-for-1 forward stock split effected by the Issuer on June 5, 2015.
- F2The option is fully vested